Modification of serum lipids and cardiovascular risk by estrogenic active compounds

Gynecological Endocrinology

Volumn 13, Issue SUPPL. 6, 1999, Pages 21-28

  Windler, E ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Cardiovascular disease; Estrogen; Lipoproteins; Selective estrogenic active compound

Indexed keywords

ANTIESTROGEN; ANTIOXIDANT; CONJUGATED ESTROGEN; EQUILIN; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTRONE SULFATE; LIPID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ARTERIOSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONFERENCE PAPER; FEMALE; HORMONE SUBSTITUTION; HUMAN; LIPID BLOOD LEVEL; LIPID OXIDATION; MENOPAUSE; PRIORITY JOURNAL; RISK FACTOR;

EID: 0033374711     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.1080/gye.13.s6.21.28     Document Type: Conference Paper

References (70)

1. Barrett-Connor E, Bush TL. Estrogen replacement and coronary heart disease. In Douglas PS, ed. Heart Disease in Women. Philadelphia: Davis, 1989: 69-86
2. Barth W, Löwel H, Lewis M, et al. Coronary heart disease mortality, morbidity, and case fatality in five East and West German cities 1985-1989. J Clin Epidemiol 1996;49:1277-84
3. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-39
4. Diabetes Study UKPDS 33. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
5. Cremer P, Nagel D, Mann H, et al. Ten-year follow-up results from the Goettingen Risk, Incidence and Prevalence Study (GRIPS). Risk factors for myocardial infarction in a cohort of 5790 men. Atherosclerosis 1997;129:221-30
6. Assmann G, Schulte H, von Eckardstein A, et al. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996; 124:S11-20
7. Razay G, Heaton KW, Bolton CH. Coronary heart disease risk factors in relation to the menopause. Q J Med New Series 1992;85:307-8
8. Grundy SM. Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. Am J Cardiol 1998;81:18B-25B
9. Sonnendecker EWW, Polakow ES, Spinnler Benadé AJ, et al. Serum lipoprotein effects of conjugated estrogen-medrogestone regimen in hysterectomized postmenopausal women. Am J Obstet Gynecol 1989;160:1128-34
10. The writing group for the PEPI trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. J Am Med Assoc 1995;273:199-208
11. Van der Mooren MJ, Gevers Leuven JA, Rolland R. Effect of conjugated estrogens with and without medrogestone: a prospective study. Maturitas 1994; 19:33-42
12. Erickson SK, Jaeckle S, Lear SR, et al. Regulation of hepatic cholesterol and lipoprotein metabolism in ethinyl estradiol-treated rats. J Lipid Res 1989; 30:1763-71
13. Pedersen TR, Olsson AG, Faergerman O, et al., for the 4S Group. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation 1998;97:1453-60
14. Kjekshus J, Pedersen TR, Pyörälä K, for the 4S Group. Impact of hypertension, diabetes and smoking on the effect of simvastatin on coronary events in coronary heart disease patients. Circulation 1995;92:1-18
15. Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991;325:1196-204
16. Heinonen TM, Schrott H, Broyles F, et al. The effects of atorvastatin in postmenopausal women. In Congress of the European Atherosclerosis Society, 66th. Florence, Italy, July 1996, p56
17. Kim CJ, Jang HC, Cho DH, et al. Effects of hormone replacement therapy on lipoprotein (a) and lipids in postmenopausal women. Arterioscler Thromb 1994;14:275-81
18. Mendoza S, Velazquez E, Osona A, et al. Postmenopausal cyclic estrogen-progestin therapy lowers lipoprotein(a). J Lab Clin Med 1994;123: 837-41
19. Sacks FM, McPherson R, Walsh BW. Effect of postmenopausal estrogen replacement on plasma Lp(a) lipoprotein concentrations. Arch Intern Med 1994;154:1106-10
20. Shewmon DA, Stock JL, Rosen CJ, et al. Tamoxifen and estrogen lower circulating lipoprotein(a) concentrations in healthy postmenopausal women. Arterioscler Thromb 1994;14: 1586-93
21. Soma MR, Osnago-Gadda I, Paoletti R, et al. The lowering of lipoprotein(a) induced by estrogen plus progesterone replacement therapy in postmenopausal women. Arch Intern Med 1993;153:1462-8
22. Brzozowski AM, Pike ACW, Dauter Z, et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997;389:753-8
23. Grese TA, Sluka JP, Bryant HU, et al. Molecular determinants of tissue selectivity in estrogen-receptor modulators. Proc Natl Acad Sci USA 1997; 94:14105-10
24. Cowley SM, Hoare S, Mosselman S, et al. Estrogen receptors α and β form heterodimers on DNA. J Biol Chem 1997;272:19858-62
25. Inoue S, Hoshino S, Miyoshi H, et al. Identification of a novel isoform of estrogen receptor, a potential inhibitor of estrogen action in vascular smooth muscle cells. Biochem Biophys Res Commun 1996; 219:766-72
26. Nickenig G, Baumer AT, Grohe C, et al. Estrogen modulates AT1 receptor gene expression in vitro and in vivo. Circulation 1998;97:2197-201
27. Paech K, Webb O, Kuper GGJM, et al. Differential ligand activation of estrogen receptors ERα and ERβ at AP1 sites. Science 1997;277:1508-10
28. Power RF, Mani SK, Codina J, et al. Dopaminergic and ligand-independent activation of steroid hormone receptors. Science 1991;254:1636-9
29. Shibata H, Spencer TE, Onate SA, et al. Role of co-activators and co-repressors in the mechanism of steroid/thyroid hormone receptor superfamily. Recent Prog Horm Res 1997;52:141-65
30. Bryant HU, Dere WH. Selective estrogen receptor modulators: an alternative to hormone replacement therapy. Proc Soc Exp Biol Med 1998;217: 45-52
31. McDonnell DP. Definition of the molecular mechanism of action of tissue-selective oestrogen-receptor modulators. Biochem Soc Trans 1998;26: 54-60
32. Rattan AK, Arad Y. Inhibition of LDL oxidation by a new estradiol receptor modulator compound LY-139478, comparative effect with other steroids. Atherosclerosis 1998;136:305-14
33. Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. J Am Med Assoc 1998;279:1445-51
34. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337:1641-7
35. Saarto T, Blomqvist C, Ehnholm C, et al. Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J Clin Oncol 1996;14:429-33
36. Bhavnani BR, Cecutti A, Dey MS. Biologic effects of delta-8-estrone sulfate in postmenopausal women. J Soc Gynecol Invest 1998;5:156-60
37. Washburn SA, Honore EK, Cline JM, et al. Effects of 17α-dihydroequilenin sulfate on athrosclerotic male and female rhesus monkeys. Am J Obstet Gynecol 1996;175:341-51
38. Wilcox JG, Hwang J, Hodis HN, et al. Cardio-protective effects of individual conjugated equine estrogens through their possible modulation of insulin resistence and oxidation of low-density lipoprotein. Fertil Steril 1997;67:57-62
39. Tang M, Abplanalp W, Ayres S, et al. Superior and distinct antioxidant effects of selected estrogen metabolites on lipid peroxidation. Metabolism 1996; 45:411-14
40. Bourassa PAK, Milos PM, Caynor VJ, et al. Estrogen reduces atherosclerotic lesion development in apolipoprotein E-deficient mice. Proc Natl Acad Sci USA 1996;93:10022-7
41. Nathan L, Chaudhuri G. Estrogens and atherosclerosis. Annu Rev Pharmacol Toxicol 1997;37:477-515
42. Sullivan TR Jr, Karas RH, Aronovitz M, et al. Estrogen inhibits the response-to-injury in a mouse carotid artery model. J Clin Invest 1995;96:2482-8
43. Sudhir K, Chou TM, Chatterjee K, et al. Premature coronary artery disease associated with a disruptive mutation in the estrogen receptor gene in a man. Circulation 1997;96:3774-7
44. Best TJM, Berger PB, Miller VM, et al. The effect of estrogen replacement therapy on plasma nitric oxide and endothelin-1 levels in postmenopausal women. Ann Intern Med 1998;128:285-8
45. Blumenthal RS, Heldman AW, Brinker JA, et al. Acute effects on conjugated estrogens on coronary blood flow response to acetylcholine in men. Am J Cardiol 1997;80:1021-4
46. Guetta V, Quyyumi AA, Prasad A, et al. The role of nitric oxide in coronary vascular effects of estrogen in postmenopausal women. Circulation 1997;96: 2795-801
47. Koh KK, Nincemoyer R, Bui MN, et al. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 1997;336: 683-90
48. Salomaa V, Rasi V, Pekkanen J, et al. Association of hormone replacement therapy with hemostatic and other cardiovascular risk factors: the FINRISK Hemostasis Study. Arterioscler Thromb Vasc Biol 1995;15:1549-55
49. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 1997;272:20963-6
50. Sack MN, Rader DJ, Cannon RO III. Oestrogen and inhibition of oxidation of low density lipoproteins in postmenopausal women. Lancet 1994; 343:269-70
51. Santanam N, Shern-Brewer R, McClatchey R, et al. Estradiol as an antioxidant: incompatible with its physiological concentrations and function. J Lipid Res 1998;39:2111-18
52. Barrett-Connor E. Sex differences in coronary heart disease: why are women so superior? The 1995 Ancel Keys Lecture. Circulation 1997;95: 252-64
53. Bush TL. Noncontraceptive estrogen use and risk of cardiovascular disease: an overview and critique of the literature. In Korenman SG (Hrsg). Menopause: Biologic and Clinical Consequences of Ovarian Failure - Evaluation and Management. Presented at Serona Symposium, Norwell, MA, USA, 1990;18: 211-33
54. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality. N Engl J Med 1997;336:1769-75
55. Kafonek SD. Postmenopausal hormone replacement therapy and cardiovascular risk reduction - a review. Drugs 1994;47:16-24
56. Mendelsohn ME, Karas RH. Estrogen and the blood vessel wall. Curr Opin Cardiol 1994;9:619-26
57. Seed M. Postmenopausal hormone replacement therapy, coronary heart disease and plasma lipoproteins. Drugs 1994;47:25-34
58. Stampfer MJ, Colditz GA. Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Preventive Med 1991;20:47-63
59. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117:1016-37
60. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996; 335:453-61
61. Psaty BM, Heckbert SR, Atkins D, et al. The risk of myocardial infarction associated with the combined use of estrogens and progestins in postmenopausal women. Arch Intern Med 1994;154: 1333-9
62. Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987;75:1102-9
63. Criqui MH, Suarez L, Barrett-Connor E, et al. Postmenopausal estrogen use and mortality. Am J Epidemiol 1988;128:606-14
64. Herdersen BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 1991;151:75-8
65. Zubialde JP, Lawler F, Clemenson N. Estimated gains in life expectancy with use of postmenopausal estrogen therapy: a decision analysis. J Fam Pract 1993;36:271-80
66. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. J Am Med Assoc 1998;280:605-13
67. Gruchow HW, Anderson AA, Barboriak JJ, et al. Postmenopausal use of estrogen and occlusion of coronary arteries. Am Heart J 1988;115: 954-63
68. O'Brian JE, Peterson ED, Keeler GP, et al. Relation between estrogen replacement therapy and restenosis after percutaneous coronary interventions. J Am Coll Cardiol 1996;28: 1111-18
69. O'Keefe JH Jr, Kim SC, Hall RR, et al. Estrogen replacement therapy after coronary angioplasty in women. J Am Coll Cardiol 1997;29:1-5
70. Sullivan JM, van der Zwaag R, Jughes J, et al. Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women. Arch Intern Med 1990;150:2557-62